Indrayani Biotech Limited Business Intelligence Report
Indrayani Biotech Limited Business Intelligence Report
Quality Scores
Latest Quarterly Earnings Summary
Loading latest quarter…
AI Summary
Indrayani Biotech Limited (IBL) is a micro-cap diversified conglomerate operating across disparate sectors including Food & Hospitality, Engineering, and Healthcare. While the business has shown aggressive revenue growth over a 3-year horizon (29% CAGR), this expansion appears to be fueled by excessive debt and capital infusions rather than operational efficiency. Recent fiscal performance shows a sharp decline, with FY25 turning into a net loss of ₹6 Cr despite a high revenue base. The business model suffers from high complexity and low segment synergy, leading to fragmented management…
Key Changes in FY2026
Indrayani Biotech has undergone a massive transformation from a small-scale entity to a diversified industrial house. Starting with a focused biotech or agriculture mandate, it has aggressively pivoted into Engineering (Matrix Boilers), Dairy (Dindigul Farm), and Hospitality (A-Diet Express). This evolution is reflected in the 5-year revenue CAGR of 126%, indicating a frantic pace of acquisitions or new segment launches. However, this diversification lacks a central synergy, moving the company into highly competitive and capital-intensive sectors. The transition from a lean balance sheet to one with ₹137 Cr in debt marks a shift toward a high-leverage growth model.
Management Commentary
Management execution is questionable given the significant mismatch between the company's diversified ambitions and its financial reality. The pursuit of multiple business units from Dairy to Infrastructure for a company of this size suggests a lack of strategic focus. While management has successfully raised equity capital to expand the balance sheet, they have struggled to maintain operational discipline, leading to the recent GST registration revocation and ITAT tax assessment disputes. The decreasing promoter holding, which fell by 12% over the last three years to 32.92%, indicates a potential reduction in skin-in-the-game. Transparency is moderate, but the frequent reporting of 'Other Income' and high related-party transactions require close scrutiny.
Financial Highlights
The financial quality of IBL is characterized by extreme volatility and thinning margins, with EBITDA margins collapsing to 4.9% in FY25 from double-digit levels in previous years. While the 5-year revenue growth looks impressive on paper, the bottom line has failed to scale, leading to a recent net loss and negative EPS of -0.78 in FY25. The interest coverage ratio has dropped to a critical 0.52x, indicating that the business is not generating enough operating profit to comfortably service its debt obligations. Return on Equity (ROE) has swung from 19.1% in FY23 to -8.4% in FY25, highlighting a lack of structural stability. The heavy reliance on 'Other Income' (₹6.47 Cr) to support earnings further obscures the weakness in core operations.
Major Opportunities
- Diversified business portfolio across Food, Hospitality, and Engineering
- Trading below historical book value multiples (0.81x)
- High 5-year revenue CAGR of 21%
Major Risks
- Severely low interest coverage ratio of 0.52x
- Massive promoter holding reduction from 72% to 32.9%
- Negative Free Cash Flow for consecutive years FY23-FY25
About Indrayani Biotech Limited's Annual Report & Financial Performance
The latest Indrayani Biotech Limited annual report (FY2026) is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis, audited financial statements, the director's report, the corporate governance and auditor's reports, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This Business Intelligence Hub consolidates the official filings with AI-generated financial analysis so investors can see how revenue, operating margin, cash flow quality, capex, dividends, net debt and management outlook have changed — without reading the entire filing.
What this Indrayani Biotech Limited research covers
- Fundamental & business analysis
- Financial statements & performance
- Management commentary & discussion
- Corporate governance & auditor report
- Cash flow analysis & capital allocation
- Valuation analysis & business quality
- Growth analysis & competitive position
- Risk, SWOT & moat analysis
- Quarterly earnings & conference-call summary
- Sector, industry & peer comparison
- Latest official company filings
- Business outlook & long-term growth
Indrayani Biotech Limited — Frequently Asked Questions
Explore more Indrayani Biotech Limited research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.